Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scotia Holdings PLC

Latest From Scotia Holdings PLC

Deal Watch: Genentech Gets Down In The Dirt With Lodo Therapeutics

Genentech and Lodo will mine the soil microbiome to discover novel therapeutics. China’s Luye licenses commercial rights to AstraZeneca’s Seroquel franchise, while Sarepta picked up rights to gene therapy candidates from Myonexus, plus an option to acquire the company.

Deals Business Strategies

UK Biotech Learns the Hard Way

A bunch of UK biotech firms are in trouble, some forced to restructure and others to seek financing on miserably expensive terms. All wish they'd raised more money during the funding bonanza of 2000. Challenging times such as these reveal lingering cracks--and lack of experience--in strategy and business management. This suggests that UK industry, although it has matured significantly since the brutal blow to confidence dealt by a major product failure at British Biotech during the sector's tender early years, still has some way to go.

BioPharmaceutical Europe

Germany's Growth Story

Germany's biotech investment has propelled a handful of companies onto the public markets a lot sooner than their US or UK counterparts. These German companies have followed aggressive acquisition strategies, most often buying into the US, sometimes using newly-minted Neuer Markt paper. Some are seeking through these acquisitions to both broaden their technology platform and acquire a product portfolio, hoping thereby to avoid the pitfalls of a narrow focus. It's too early to tell whether such a dual model will work. But the fact that Germany's young companies are finding their own approach to competing globally shows that the country's biotech initiative has already had some success.

BioPharmaceutical Europe

Innovation Without Discovery

What's the fastest, lowest-risk route to an approved drug? Develop somebody else's clinical-stage therapeutic. But finding them is tough--and to get a reasonable return on investment, the in-licensor needs to bring value the originator couldn't.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology